BWAY
BrainsWay Ltd.
$14.89
+$0.39(+2.69%)
27
Overall
35
Value
20
Tech
--
Quality
Market Cap
$278.89M
Volume
45.21K
52W Range
$7.84 - $17.92
Target Price
$20.00
Company Overview
| Mkt Cap | $278.89M | Price | $14.89 |
| Volume | 45.21K | Change | +2.69% |
| P/E Ratio | 95.5 | Open | $14.37 |
| Revenue | $41.0M | Prev Close | $14.50 |
| Net Income | $2.9M | 52W Range | $7.84 - $17.92 |
| Div Yield | N/A | Target | $20.00 |
| Overall | 27 | Value | 35 |
| Quality | -- | Technical | 20 |
No chart data available
About BrainsWay Ltd.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Sector: Healthcare
Industry: Diagnostics & Research
Latest News
BrainsWay Initiates Clinical Trial for Alcohol Use Disorder
TipRanks Auto-Generated Newsdesk•6 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BWAY | $14.89 | +2.7% | 45.21K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |